The FDA has raised deep concerns with ImprimisRx over “false and misleading” promotional materials for its eyedrop therapy Pred-Moxi-Brom, which is used to manage pain and inflammation after surgeries ...
MISSOULA, Mont.--(BUSINESS WIRE)-- OSRX, Inc. today expressed its profound disappointment with the recent jury verdict in the case of ImprimisRx, LLC v. OSRX, Inc. The company believes the decision to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results